Literature DB >> 21029375

OPRM1 gene variants modulate amphetamine-induced euphoria in humans.

A M Dlugos1, A Hamidovic, C Hodgkinson, P H Shen, D Goldman, A A Palmer, H de Wit.   

Abstract

The μ-opioid receptor is involved in the rewarding effects of not only opioids like morphine but also psychostimulants like amphetamine. This study aimed to investigate associations between subjective response to amphetamine and genetic polymorphisms and haplotypes in the μ-opioid receptor including the exonic variant rs1799971 (Asp40Asn). One hundred and sixty-two Caucasian volunteers participated in three sessions receiving either placebo or d-amphetamine (10 and 20 mg). Associations between levels of self-reported Euphoria, Energy and Stimulation [Addiction Research Center Inventory 49-item questionnaire (ARCI-49)] after d-amphetamine ingestion and polymorphisms in OPRM1 were investigated. The intronic single nucleotide polymorphisms (SNPs) rs510769 and rs2281617 were associated with significantly higher ratings of Euphoria, Energy and Stimulation after 10 mg amphetamine. Feelings of Euphoria, Energy and Stimulation were also found to be associated with a two-SNP haplotype formed with rs1799971 and rs510769 and a three-SNP haplotype formed with rs1918760, rs2281617 and rs1998220. These results support the hypothesis that genetic variability in the μ-opioid receptor gene influences the subjective effects of amphetamine and may suggest new strategies for prevention and treatment of psychostimulant abuse.
© 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029375      PMCID: PMC3377371          DOI: 10.1111/j.1601-183X.2010.00655.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  51 in total

Review 1.  Understanding polydrug use: review of heroin and cocaine co-use.

Authors:  Francesco Leri; Julie Bruneau; Jane Stewart
Journal:  Addiction       Date:  2003-01       Impact factor: 6.526

2.  Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.

Authors:  Thomas J Spencer; Howard B Abikoff; Daniel F Connor; Joseph Biederman; Steven R Pliszka; Samuel Boellner; Stephanie C Read; Raymond Pratt
Journal:  Clin Ther       Date:  2006-03       Impact factor: 3.393

3.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

4.  Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Authors:  Katarina Drakenberg; Andrej Nikoshkov; Monika Cs Horváth; Pernilla Fagergren; Anna Gharibyan; Kati Saarelainen; Sadia Rahman; Ingrid Nylander; Georgy Bakalkin; Jovan Rajs; Eva Keller; Yasmin L Hurd
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

5.  Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

Authors:  Jörn Lötsch; Carsten Skarke; Johannes Wieting; Bruno Georg Oertel; Helmut Schmidt; Jürgen Brockmöller; Gerd Geisslinger
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

6.  A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances.

Authors:  J A Schinka; T Town; L Abdullah; F C Crawford; P I Ordorica; E Francis; P Hughes; A B Graves; J A Mortimer; M Mullan
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

7.  Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving.

Authors:  David A Gorelick; Yu Kyeong Kim; Badreddine Bencherif; Susan J Boyd; Richard Nelson; Marc Copersino; Christopher J Endres; Robert F Dannals; J James Frost
Journal:  Biol Psychiatry       Date:  2005-06-15       Impact factor: 13.382

8.  Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms.

Authors:  S Ide; H Kobayashi; H Ujike; N Ozaki; Y Sekine; T Inada; M Harano; T Komiyama; M Yamada; M Iyo; N Iwata; K Tanaka; H Shen; K Iwahashi; M Itokawa; M Minami; M Satoh; K Ikeda; I Sora
Journal:  Pharmacogenomics J       Date:  2006 May-Jun       Impact factor: 3.550

9.  Gene expression differences in mice divergently selected for methamphetamine sensitivity.

Authors:  Abraham A Palmer; Miguel Verbitsky; Rathi Suresh; Helen M Kamens; Cheryl L Reed; Na Li; Sue Burkhart-Kasch; Carrie S McKinnon; John K Belknap; T Conrad Gilliam; Tamara J Phillips
Journal:  Mamm Genome       Date:  2005-05       Impact factor: 2.957

10.  Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase.

Authors:  Tara L White; Angela J H Justice; Harriet de Wit
Journal:  Pharmacol Biochem Behav       Date:  2002-11       Impact factor: 3.533

View more
  22 in total

1.  Prenatal exposure to cigarette smoke interacts with OPRM1 to modulate dietary preference for fat.

Authors:  Ken W K Lee; Michal Abrahamowicz; Gabriel T Leonard; Louis Richer; Michel Perron; Suzanne Veillette; Eva Reischl; Luigi Bouchard; Daniel Gaudet; Tomas Paus; Zdenka Pausova
Journal:  J Psychiatry Neurosci       Date:  2015-01       Impact factor: 6.186

Review 2.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 3.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

4.  COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation.

Authors:  Keith G Heinzerling; James T McCracken; Aimee-Noelle Swanson; Lara A Ray; Steven J Shoptaw
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

5.  Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Authors:  Emily C Eastwood; Amy J Eshleman; Aaron Janowsky; Tamara J Phillips
Journal:  Mamm Genome       Date:  2017-11-10       Impact factor: 2.957

6.  The drug effects questionnaire: psychometric support across three drug types.

Authors:  Meghan E Morean; Harriet de Wit; Andrea C King; Mehmet Sofuoglu; Sandra Y Rueger; Stephanie S O'Malley
Journal:  Psychopharmacology (Berl)       Date:  2012-12-28       Impact factor: 4.530

7.  Sweet taste pleasantness is modulated by morphine and naltrexone.

Authors:  Marie Eikemo; Guro E Løseth; Tom Johnstone; Johannes Gjerstad; Frode Willoch; Siri Leknes
Journal:  Psychopharmacology (Berl)       Date:  2016-08-18       Impact factor: 4.530

8.  Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids.

Authors:  Camron D Bryant; Clarissa C Parker; Lili Zhou; Christopher Olker; Ramalakshmi Y Chandrasekaran; Travis T Wager; Valerie J Bolivar; Andrew S Loudon; Martha H Vitaterna; Fred W Turek; Abraham A Palmer
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

9.  The amphetamine response moderates the relationship between negative emotionality and alcohol use.

Authors:  Kenneth J D Allen; Frances H Gabbay
Journal:  Alcohol Clin Exp Res       Date:  2012-12-14       Impact factor: 3.455

10.  Opioid receptor mu 1 gene, fat intake and obesity in adolescence.

Authors:  A Haghighi; M G Melka; M Bernard; M Abrahamowicz; G T Leonard; L Richer; M Perron; S Veillette; C J Xu; C M T Greenwood; A Dias; A El-Sohemy; D Gaudet; T Paus; Z Pausova
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.